Dual Antiplatelet Therapy in Coronary Artery Disease: Comparison Between ACC/AHA 2016 and ESC 2017 Guidelines
Dual antiplatelet therapy (DAPT) is integral to the management of coronary artery disease (CAD) but there remains uncertainty as to the optimal approach for balancing an individual’s risk of atherothrombotic events versus their risk of bleeding complications. A myriad of clinical trials have investi...
Guardado en:
Autor principal: | Christopher N Floyd |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Radcliffe Medical Media
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/74b5438467c548f8b24cc02460b08679 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Type and Duration of Dual Antiplatelet Therapy in Complex Percutaneous Coronary Intervention
por: Dimitrios Alexopoulos, et al.
Publicado: (2020) -
The 2020 ESC Guidelines on the Diagnosis and Management of Atrial Fibrillation
por: Agnieszka Kotalczyk, et al.
Publicado: (2021) -
Oral Anticoagulant and Antiplatelet
Therapy for Cervical Artery Dissection: A Meta-Analysis of Clinical Trials
por: Sheng-Lin Ye MD, et al.
Publicado: (2021) -
An extremely rare coronary artery anomaly: Monster left anterior descending coronary artery
por: Savaş Çelebi, et al.
Publicado: (2021) -
Stroke of antiplatelet and anticoagulant therapy in patients with coronary artery disease: a meta-analysis of randomized controlled trials
por: Qiao Yu Shao, et al.
Publicado: (2021)